Northwest Technology Ventures

Adapx, Inc. is a technology company that specializes in user interface software solutions designed to enhance data capture and operational efficiency for businesses and government agencies. Its flagship product, Capturx, seamlessly converts natural speech, sketches, and handwriting into structured data, streamlining workflows and minimizing the need for manual data transcription. Capturx offers various applications, including integrations for Microsoft Office, SharePoint, and ArcGIS, along with mobile solutions for data collection. The company caters to diverse sectors, including manufacturing, defense, health, and utilities, and provides additional services such as mobile workflow analysis and design optimization. Founded in 1999 and based in Seattle, Washington, Adapx has established strategic partnerships with notable organizations like Microsoft and ESRI, enhancing its capabilities and reach in the market.

Adapx, Inc. is a technology company that specializes in user interface software solutions designed to enhance data capture and operational efficiency for businesses and government agencies. Its flagship product, Capturx, seamlessly converts natural speech, sketches, and handwriting into structured data, streamlining workflows and minimizing the need for manual data transcription. Capturx offers various applications, including integrations for Microsoft Office, SharePoint, and ArcGIS, along with mobile solutions for data collection. The company caters to diverse sectors, including manufacturing, defense, health, and utilities, and provides additional services such as mobile workflow analysis and design optimization. Founded in 1999 and based in Seattle, Washington, Adapx has established strategic partnerships with notable organizations like Microsoft and ESRI, enhancing its capabilities and reach in the market.

DesignMedix, Inc. is a pharmaceutical drug development company focused on creating small molecule drugs to combat drug resistance in infectious diseases. Founded in 2006 and based in Portland, Oregon, the company is known for its drug candidate DM1157, which aims to provide a cure for drug-resistant malaria, particularly in vulnerable populations such as children and pregnant women. In addition to malaria, DesignMedix is developing treatments for other conditions, including trichomonas vaginalis, helicobacter pylori, and various bacterial and parasitic diseases. The company's innovative approach involves covalently linking a chemical moiety from a resistance reversal agent to serve dual purposes as both a therapeutic and a resistance reversal agent, thereby facilitating more effective treatment options for healthcare providers.

Translarity, headquartered in Silicon Valley, specializes in innovative semiconductor wafer testing solutions, focusing on advanced probe card markets. The company pioneers full-wafer testing with low cost, high performance, and short cycle times. In 2017, Translarity acquired BucklingBeam to expand its offerings, now providing a comprehensive suite of probe card solutions including full probe cards and vertical probe head solutions. Leveraging its proprietary Space Translator™ technology, Translarity addresses the rapid evolution in probe technologies. Led by an experienced management team and supported by strong financial investors, Translarity has recruited top industry talent to develop Wafer Translator™ technology, resulting in a robust IP portfolio with over 45 issued patents and more than 50 filed.

AboutUs.org is a freely editable wiki internet domain directory that lists websites along with information about their content.

Receptor BioLogix is a biotechnology company based in Palo Alto, California, focused on developing receptor-based biological therapeutics aimed at treating cancer, inflammatory, and autoimmune diseases. The company specializes in creating Hermodulins, which are pan-HER ligand traps designed to inhibit the compensatory feedback mechanisms that can reduce the effectiveness and longevity of various cancer treatments. Additionally, Receptor BioLogix utilizes its Intron Fusion Protein platform to discover novel splice variants of human proteins, which hold therapeutic potential. Through these innovative approaches, the company aims to enhance treatment options and improve outcomes for patients with challenging medical conditions.

Artielle ImmunoTherapeutics, Inc. is a biopharmaceutical company based in Tigard, Oregon, established in 2004. The company specializes in developing biologic drugs that target inflammatory and degenerative diseases, with a particular focus on neuro-inflammatory conditions. Artielle's platform includes recombinant T-cell receptor ligands (RTLs), which are designed to treat T-cell mediated inflammatory diseases. Key areas of development include therapies for multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, and optic neuritis. By targeting the CD74 receptor on monocytes and inhibiting the action of macrophage migration inhibitory factor, Artielle ImmunoTherapeutics aims to provide innovative solutions for patients suffering from these challenging conditions.

IP Fabrics, Inc. is a US-based company specializing in network visibility, compliance, and analytics solutions for various sectors, including telecommunications, cable, and government agencies. Founded in 2002 and headquartered in Beaverton, Oregon, the company offers a range of products designed for network surveillance and diagnostics. Its product suite includes TunnelBox, a remote traffic access appliance, and DeepProbe, a deep packet inspection device that provides real-time alerts for network events. The DeepSweep appliance supports lawful intercept compliance and enhances network visibility. Additionally, the company offers CyberInsight, an analytics solution for network behavior analysis, as well as an OpenIntelligence software development kit for customizable applications. IP Fabrics serves over 50 customers, including service providers and law enforcement agencies, and provides ongoing support, training, and maintenance for its solutions. As of mid-2015, IP Fabrics operates as a subsidiary of Yaana Technologies, LLC.

Ambric is a developer and manufacturer of software-programmable interface circuits that utilize a massively parallel processor array architecture. The company specializes in high-performance applications, particularly in media processing and medical imaging. Ambric's first generation chip architecture, known as the Am2045, integrates 336 processors on a single chip, providing a competitive alternative to large FPGAs, DSPs, and Intel x86 processors commonly used in embedded markets. The company's innovative parallel processor solution includes a structured object programming model, which facilitates effective programming for developers managing a large number of cores. Ambric has strategically targeted various sectors, including video compression, medical imaging, wireless base stations, and military applications.